

Max Peters

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6214951/publications.pdf>

Version: 2024-02-01

103
papers

1,614
citations

331670

21
h-index

345221

36
g-index

112
all docs

112
docs citations

112
times ranked

1859
citing authors

#	ARTICLE	IF	CITATIONS
1	Bedside teaching in medical education: a literature review. <i>Perspectives on Medical Education</i> , 2022, 3, 76-88.	3.5	186
2	Adjuvant Treatment Following Irradical Resection of Stage I-III Non-small Cell Lung Cancer: A Population-based Study. <i>Current Problems in Cancer</i> , 2022, 46, 100784.	2.0	0
3	Non-Small-Cell Lung Cancer Patients with a High Predicted Risk of Irradical Resection: Can Chemoradiotherapy Offer Similar Survival?. <i>Annals of Surgical Oncology</i> , 2022, 29, 1807-1814.	1.5	1
4	ASO Visual Abstract: Non-small Cell Lung Cancer Patients with a High Predicted Risk of Irradical Resection can Chemoradiotherapy Offer Similar Survival?. <i>Annals of Surgical Oncology</i> , 2022, 29, 1815-1815.	1.5	1
5	Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. <i>European Urology</i> , 2022, 81, 407-413.	1.9	41
6	Value of Targeted Biopsies and Combined PSMA PET/CT and mp-MRI Imaging in Locally Recurrent Prostate Cancer after Primary Radiotherapy. <i>Cancers</i> , 2022, 14, 781.	3.7	8
7	The overall survival impact of prophylactic cranial irradiation in limited-stage small-cell lung cancer: A systematic review and meta-analysis. <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 145-152.	1.7	4
8	Upstaging by para-aortic lymph node dissection in patients with locally advanced cervical cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2022, 164, 667-674.	1.4	12
9	Prognostic impact of waiting time between diagnosis and treatment in patients with cervical cancer: A nationwide population-based study. <i>Gynecologic Oncology</i> , 2022, 165, 339-346.	1.4	1
10	In Reply to Chow and Simone. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 236-237.	0.8	0
11	The impact of para-aortic lymph node irradiation on disease-free survival in patients with cervical cancer: A systematic review and meta-analysis. <i>Clinical and Translational Radiation Oncology</i> , 2022, 35, 97-103.	1.7	2
12	Functional and oncological outcomes of salvage cryosurgery for radiorecurrent prostate cancer. <i>BJU International</i> , 2021, 128, 46-56.	2.5	4
13	Predicting Incomplete Resection in Non-Small Cell Lung Cancer Preoperatively: A Validated Nomogram. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1052-1058.	1.3	8
14	Long-term outcomes of two ablation techniques for treatment of radio-recurrent prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 186-192.	3.9	2
15	Assessment of Return to Baseline Urinary and Sexual Function Following Primary Focal Cryotherapy for Nonmetastatic Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 301-308.	3.1	11
16	Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 567-574.	3.9	28
17	Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patients. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 1-7.	1.7	5
18	Prophylactic cranial irradiation in patients with small cell lung cancer in The Netherlands: A population-based study. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 157-163.	1.7	7

#	ARTICLE	IF	CITATIONS
19	Evaluation of daily online contour adaptation by radiation therapists for prostate cancer treatment on an MRI-guided linear accelerator. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 50-56.	1.7	32
20	A Comparison of Prostate Cancer Detection between Visual Estimation (Cognitive Registration) and Image Fusion (Software Registration) Targeted Transperineal Prostate Biopsy. <i>Journal of Urology</i> , 2021, 205, 1075-1081.	0.4	23
21	61MO Safety and efficacy of protracted stereotactic body radiotherapy for ultra-central lung tumours. <i>Journal of Thoracic Oncology</i> , 2021, 16, S729.	1.1	0
22	Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1120-1128.	3.9	10
23	Can quantitative analysis of multi-parametric MRI independently predict failure of focal salvage HIFU therapy in men with radio-recurrent prostate cancer?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 830.e1-830.e8.	1.6	5
24	Ultra-central lung tumors: safety and efficacy of protracted stereotactic body radiotherapy. <i>Acta Oncologica</i> , 2021, 60, 1061-1068.	1.8	25
25	MR compatibility, safety and accuracy of the redesigned UMC Utrecht single needle implant device. <i>Physics in Medicine and Biology</i> , 2021, 66, 12NT02.	3.0	0
26	In Reply to Murgic and Chung. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 618-619.	0.8	0
27	Focal ablative salvage therapy for radio-recurrent prostate cancer: 6 year oncological and safety outcomes. <i>European Urology</i> , 2021, 79, S1693-S1694.	1.9	0
28	Progression-free survival in patients with ⁶⁸ Ga-PSMA-PET-directed SBRT for lymph node oligometastases. <i>Acta Oncologica</i> , 2021, 60, 1342-1351.	1.8	9
29	The Influence of Severe Radiation-Induced Lymphopenia on Overall Survival in Solid Tumors: A Systematic Review and Meta-Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 936-948.	0.8	53
30	Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva: An efficacy study. <i>Gynecologic Oncology</i> , 2021, 163, 117-124.	1.4	11
31	MPO5-15â€fTRANSPERINEAL VS TRANSRECTAL MICRO-ULTRASOUND AND MPMRI TARGETED PROSTATE BIOPSIES: PROPENSITY SCORE-MATCHED STUDY. <i>Journal of Urology</i> , 2021, 206, .	0.4	0
32	Development and internal validation of multivariable prediction models for biochemical failure after MRI-guided focal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer. <i>Clinical and Translational Radiation Oncology</i> , 2021, 30, 7-14.	1.7	4
33	Severe lymphopenia acquired during chemoradiotherapy for esophageal cancer: Incidence and external validation of a prediction model. <i>Radiotherapy and Oncology</i> , 2021, 163, 192-198.	0.6	6
34	Risk factors for nodal failure after radiochemotherapy and image guided brachytherapy in locally advanced cervical cancer: An EMBRACE analysis. <i>Radiotherapy and Oncology</i> , 2021, 163, 150-158.	0.6	12
35	Prediction of Severe Lymphopenia During Chemoradiation Therapy for Esophageal Cancer: Development and Validation of a Pretreatment Nomogram. <i>Practical Radiation Oncology</i> , 2020, 10, e16-e26.	2.1	42
36	Likert vs PIâ€RADS v2: a comparison of two radiological scoring systems for detection of clinically significant prostate cancer. <i>BJU International</i> , 2020, 125, 49-55.	2.5	42

#	ARTICLE	IF	CITATIONS
37	A contemporary analysis of radical orchidectomy for testis cancer. <i>European Urology Open Science</i> , 2020, 19, e2221-e2222.	0.4	0
38	Man vs machine: Comparative effectiveness of cognitive targeted and image-fusion targeted transperineal prostate biopsy. <i>European Urology Open Science</i> , 2020, 19, e2289.	0.4	0
39	Health-related quality of life after ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: reporting the patient's perspective. <i>Clinical and Translational Radiation Oncology</i> , 2020, 25, 81-87.	1.7	1
40	Patient-Reported Outcomes of Oligometastatic Patients After Conventional or Stereotactic Radiation Therapy to Bone Metastases: An Analysis of the PRESENT Cohort. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 39-47.	0.8	16
41	Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry. <i>BJU International</i> , 2020, 125, 853-860.	2.5	23
42	MRI-Guided Ultrafocal Salvage High-Dose-Rate Brachytherapy for Localized Radiorecurrent Prostate Cancer: Updated Results of 50 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 126-135.	0.8	23
43	PD14-04 DEVELOPMENT OF A RISK CALCULATOR TO PREDICT SPONTANEOUS STONE PASSAGE IN PATIENTS WITH ACUTE URETERIC COLIC. <i>Journal of Urology</i> , 2020, 203, .	0.4	1
44	MP56-11 THE RAPID RISK SCORE. <i>Journal of Urology</i> , 2020, 203, e851-e852.	0.4	0
45	MP81-12 MRI COMPARED TO DRE STAGING FOR PROSTATE CANCER: A WILL ROGERS PHENOMENON. <i>Journal of Urology</i> , 2020, 203, .	0.4	0
46	MP56-02 MAN VS. MACHINE: COMPARATIVE EFFECTIVENESS OF COGNITIVE TARGETED AND IMAGE-FUSION TARGETED TRANSPERINEAL PROSTATE BIOPSY. <i>Journal of Urology</i> , 2020, 203, .	0.4	0
47	OC-0566: Risk factors for nodal failure in the EMBRACE study cohort. <i>Radiotherapy and Oncology</i> , 2020, 152, S315-S316.	0.6	0
48	Intraprostatic Cancer Recurrence following Radical Radiotherapy on Transperineal Template Mapping Biopsy: Implications for Focal Ablative Salvage Therapy. <i>Journal of Urology</i> , 2020, 204, 950-955.	0.4	6
49	In Reply to David and Kamrava. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1183-1184.	0.8	0
50	MRI-Guided Ultrafocal HDR Brachytherapy for Localized Prostate Cancer: Median 4-Year Results of a feasibility study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1045-1053.	0.8	26
51	PO-0795 Prediction of severe lymphopenia during chemoradiotherapy for esophageal cancer. <i>Radiotherapy and Oncology</i> , 2019, 133, S411.	0.6	0
52	Reply to Zhipeng Mai's Letter to the Editor re: Taimur T. Shah, Max Peters, David Eldred-Evans, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. <i>Eur Urol</i> 2019;76:98-105. <i>European Urology</i> , 2019, 76, e63-e64.	1.9	0
53	Factors associated with spontaneous stone passage in a contemporary cohort of patients presenting with acute ureteric colic: results from the Multi-centre cohort study evaluating the role of Inflammatory Markers In patients presenting with acute ureteric Colic (MIMIC) study. <i>BJU International</i> , 2019, 124, 504-513.	2.5	32
54	P1.17-39 Preoperative Prediction of Incomplete Resection in Non-Small Cell Lung Cancer: An Externally Validated Clinical Nomogram. <i>Journal of Thoracic Oncology</i> , 2019, 14, S623.	1.1	0

#	ARTICLE	IF	CITATIONS
55	Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. <i>European Urology</i> , 2019, 76, 98-105.	1.9	96
56	Treating benign ureteroenteric strictures: 27-year experience comparing endourological techniques with open surgical approach. <i>World Journal of Urology</i> , 2019, 37, 1217-1223.	2.2	10
57	MP78-03â€¦TUMOR CONTROL OUTCOMES OF SALVAGE CRYOTHERAPY FOR RADIORECURRENT PROSTATE CANCER AT MEDIAN 12 YEARS FOLLOW-UP. <i>Journal of Urology</i> , 2019, 201, .	0.4	0
58	MP78-10â€¦A COMPARISON OF CANCER CONTROL OUTCOMES AT 5 YEARS OF FOCAL THERAPY (USING HIFU & Tj ETQq0 0 0 rgBT /O CANCER: PROPENSITY SCORE-MATCHED ANALYSIS. <i>Journal of Urology</i> , 2019, 201, .	0.4	0
59	MP78-06â€¦MEDIAN 5-YEAR ONCOLOGICAL OUTCOMES OF SALVAGE HIGH INTENSITY FOCUSED ULTRASOUND FOR PROSTATE CANCER RECURRENCES AFTER PRIMARY RADIOTHERAPY. <i>Journal of Urology</i> , 2019, 201, .	0.4	0
60	MP30-11 PREDICTORS OF POOR FUNCTIONAL OUTCOMES AFTER FOCAL HIGH INTENSITY FOCUSED ULTRASOUND (HIFU). <i>Journal of Urology</i> , 2018, 199, .	0.4	0
61	The effect of catheter displacement and anatomical variations on the dose distribution in MRI-guided focal HDR brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2018, 17, 68-77.	0.5	12
62	Development and internal validation of prediction models for biochemical failure and composite failure after focal salvage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for individual patient prognoses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 13.e1-13.e10.	1.6	11
63	1955. Propensity Score-Matched Comparison of Focal High Intensity Focused Ultrasound (HIFU) to Laparoscopic Radical Prostatectomy (LRP) for Clinically Significant Localised Prostate Cancer. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1834.	1.0	1
64	1957. T-Stage Migration by Routine Pre-Biopsy MRI Staging May Affect Risk Assessment with Current Risk Classification Systems. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1834-1835.	1.0	0
65	Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives. <i>Cancers</i> , 2018, 10, 480.	3.7	24
66	A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2018, 74, 422-429.	1.9	220
67	MRI guided focal HDR brachytherapy for localized prostate cancer: Toxicity, biochemical outcome and quality of life. <i>Radiotherapy and Oncology</i> , 2018, 129, 554-560.	0.6	18
68	MP16-15 T-STAGE MIGRATION WITH ROUTINE MRI STAGING MAY IMPACT ON RISK ASSESSMENT WITH CURRENT RISK CALCULATORS. <i>Journal of Urology</i> , 2018, 199, .	0.4	0
69	Re-salvage MRI-guided Focal High-dose-rate Brachytherapy for Locally Recurrent Prostate Cancer. <i>Cureus</i> , 2018, 10, e2429.	0.5	1
70	Reply to: 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. Hamdy et al. <i>NEJM</i> October 2016. <i>World Journal of Urology</i> , 2017, 35, 1465-1465.	2.2	0
71	Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. <i>European Journal of Cancer</i> , 2017, 73, 38-47.	2.8	101
72	Focal salvage highâ€¦intensity focused ultrasound in radiorecurrent prostate cancer. <i>BJU International</i> , 2017, 120, 246-256.	2.5	39

#	ARTICLE	IF	CITATIONS
73	Adaptive cone-beam CT planning improves long-term biochemical disease-free survival for 125 I prostate brachytherapy. <i>Brachytherapy</i> , 2017, 16, 282-290.	0.5	9
74	An easy-to-use scoring index to determine severity of mitral regurgitation by 2D echocardiography in clinical practice. <i>Echocardiography</i> , 2017, 34, 1275-1283.	0.9	4
75	Salvage brachytherapy for radiorecurrent prostate cancer: Searching for safety and success. <i>Brachytherapy</i> , 2017, 16, 1099-1100.	0.5	2
76	OC-0276: Toward adaptive MR-guided HDR prostate brachytherapy - Simulation study based on anatomy movements. <i>Radiotherapy and Oncology</i> , 2017, 123, S142-S143.	0.6	0
77	MP70-07 A MULTIVARIABLE MODEL AND RISK SCORE FOR BIOCHEMICAL FAILURE AFTER WHOLE-GLAND SALVAGE CRYOSURGERY AT 10 YEARS FOLLOW-UP.. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
78	Development and Internal Validation of a Clinical Risk Score to Predict Pain Response After Palliative Radiation Therapy in Patients With Bone Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 859-866.	0.8	20
79	Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 1194-1201.	1.9	37
80	Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer. <i>Journal of Contemporary Brachytherapy</i> , 2017, 2, 161-166.	0.9	10
81	Comparative cost-effectiveness of focal and total salvage 125 I brachytherapy for recurrent prostate cancer after primary radiotherapy. <i>Journal of Contemporary Brachytherapy</i> , 2016, 6, 484-491.	0.9	4
82	HG-28 SURVIVAL BENEFIT FOR PATIENTS WITH DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) UNDERGOING RE-IRRADIATION AT FIRST PROGRESSION: ANALYSIS OF THE SIOP-E-DIPG/HGG WORKING GROUP. <i>Neuro-Oncology</i> , 2016, 18, iii53.3-iii53.	1.2	0
83	MP18-02 DEVELOPMENT AND INTERNAL VALIDATION OF A MULTIVARIABLE PREDICTION MODEL FOR BIOCHEMICAL FAILURE AFTER FOCAL SALVAGE HIGH INTENSITY FOCUSED ULTRASOUND FOR LOCALLY RECURRENT PROSTATE CANCER: PRESENTATION OF A RISK SCORE FOR INDIVIDUAL PATIENT PROGNOSIS.. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
84	620 Complication rates after radical cystectomy following any previous abdominal-pelvic-perineal radiotherapy: An international, multicenter retrospective study on 609 cases. <i>European Urology Supplements</i> , 2016, 15, e620-e620a.	0.1	0
85	Rectal dose constraints for salvage iodine-125 prostate brachytherapy. <i>Brachytherapy</i> , 2016, 15, 85-93.	0.5	23
86	Multivariable model development and internal validation for prostate cancer specific survival and overall survival after whole-gland salvage Iodine-125 prostate brachytherapy. <i>Radiotherapy and Oncology</i> , 2016, 119, 104-110.	0.6	10
87	PSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 311-316.	3.9	16
88	PV-0038: Multivariable model development for mortality after total salvage Iodine-125 prostate brachytherapy. <i>Radiotherapy and Oncology</i> , 2016, 119, S16.	0.6	0
89	PV-0040: MRI guided focal primary and (secondary) salvage HDR-BT in prostate cancer patients seems safe. <i>Radiotherapy and Oncology</i> , 2016, 119, S16-S17.	0.6	0
90	OC-0064: A prediction model for biochemical failure after salvage Iodine-125 prostate brachytherapy. <i>Radiotherapy and Oncology</i> , 2016, 119, S28-S29.	0.6	0

#	ARTICLE	IF	CITATIONS
91	PO-0974: Urethral and bladder dose of total and focal salvage brachytherapy: toxicity and dose constraints. Radiotherapy and Oncology, 2016, 119, S474.	0.6	0
92	OC-0066: Adaptive cone-beam CT planning improves progression-free survival for I-125 prostate brachytherapy. Radiotherapy and Oncology, 2016, 119, S29.	0.6	0
93	PO-0769: Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation. Radiotherapy and Oncology, 2016, 119, S360.	0.6	0
94	Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review. World Journal of Urology, 2016, 34, 1521-1531.	2.2	56
95	Development and internal validation of a multivariable prediction model for biochemical failure after whole-gland salvage iodine-125 prostate brachytherapy for recurrent prostate cancer. Brachytherapy, 2016, 15, 296-305.	0.5	17
96	OC-0035: Catheter displacement and dosimetry for single fraction MRI guided focal prostate HDR brachytherapy. Radiotherapy and Oncology, 2015, 115, S16-S17.	0.6	0
97	OC-0136: Rectal dose constraints for total and focal salvage Iodine-125 prostate brachytherapy. Radiotherapy and Oncology, 2015, 115, S64.	0.6	0
98	Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints. Radiotherapy and Oncology, 2015, 117, 262-269.	0.6	22
99	Who can do without patients?. Perspectives on Medical Education, 2015, 4, 98-99.	3.5	0
100	Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: A retrospective study regarding toxicity, biochemical outcome and quality of life. Radiotherapy and Oncology, 2014, 112, 77-82.	0.6	85
101	OC-0072: Focal salvage Iodine-125 brachytherapy for recurrent prostate cancer after primary radiotherapy. Radiotherapy and Oncology, 2014, 111, S27.	0.6	0
102	Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review. World Journal of Urology, 2013, 31, 403-409.	2.2	43
103	OC-33 COMPARATIVE COST-EFFECTIVENESS OF SALVAGE BRACHYTHERAPY VS. HORMONAL TREATMENT OF RECURRENT PROSTATE CANCER. Radiotherapy and Oncology, 2012, 103, S13-S14.	0.6	0